LOS ANGELES (October 21, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the appointment of William J. Sandborn, M.D. to its Medical Advisory Board.
Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals, commented, ”We are excited to have Dr. Sandborn join Ritter Pharmaceuticals as a member of our Medical Advisory Board. His years of experience in gastroenterology, vast industry knowledge and close relationships with the FDA will be a valuable resource as we advance our development of therapeutics to treat gastrointestinal diseases, and in particular our lead product candidate RP-G28 for patients with lactose intolerance. We look forward to working with Dr. Sandborn and the contributions he will make to our team.”
Dr. Sandborn serves as the Chief, Division of Gastroenterology and Director at University of California San Diego Inflammatory Bowel Disease Center and Professor of Clinical Medicine. He has published more than 408 articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research includes clinical development and clinical pharmacology related to inflammatory bowel disease. From April 1993 to December 2010, Dr. Sandborn was head of the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN and from January 2011 to present, the Division of Gastroenterology, University of California San Diego, La Jolla. Dr. Sandborn is extremely well regarded and well known within the investment community and is considered one of the key leading gastroenterologists in the United States for pharmaceutical research and clinical trial work.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.
This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Such statements involve a number of known and unknown risks and uncertainties that could cause the company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Any statements contained herein that do not describe historical facts, including but not limited to, statements regarding Dr. Sandborn’s expected contributions to Ritter Pharmaceuticals as a member of the Medical Advisory Board, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.